Allergan (AGN) Tops Q4 EPS by 12c, Reports Mixed FY Guidance

(Updated - February 6, 2018 7:08 AM EST)

Allergan (NYSE: AGN) reported Q4 EPS of $4.86, $0.12 better than the analyst estimate of $4.74. Revenue for the quarter came in at $4.33 billion versus the consensus estimate of $4.28 billion.

GUIDANCE:

Allergan sees 2018 EPS of $15.25-$16.00, versus the consensus of $15.50. Allergan sees 2018 revenue of $15-15.3 billion, versus the consensus of $15.33 billion.

• Q1 EPS is seen at $3.20-$3.40 vs $3.71 expected with revenue of $3.5-$3.6 billion vs $3.72 billion.

For earnings history and earnings-related data on Allergan (AGN) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Needham Reiterates Buy Rating on Veeva Systems (VEEV)
• NAPCO Security Tech (NSSC) Tops Q4 EPS by 11c